MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

Rhea-AI Summary

MiNK Therapeutics (NASDAQ: INKT) has announced an upcoming presentation at the ASCO GI Symposium in San Francisco from January 23-25, 2025. The presentation will focus on their ongoing Phase 2 study of agenT-797, an invariant natural killer T (iNKT) cell therapy, combined with Agenus' botensilimab/balstilimab for treating refractory gastric cancer.

The abstract (TPS515), titled 'A phase II study of agenT-797, botensilimab, and balstilimab in patients with advanced, refractory gastroesophageal adenocarcinoma,' will be presented by Dr. Samuel Cytryn during the Trials in Progress Poster Session on January 23, 2025. Complete abstracts will be released on January 21st, 2025, at 5:00 PM ET, with presentation materials later available on MiNK's website.

News Market Reaction – INKT

-14.02%

-14.02% Session move

In the trading session that priced this news, INKT declined 14.02%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Presentation will feature the ongoing Phase 2 study of agenT-797 in refractory gastric cancer

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced a presentation at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium that will take place on January 23-25, 2025, in San Francisco, California. The poster presentation will highlight the ongoing Phase 2 study of agenT-797 in combination with Agenus’ botensilimab/balstilimab in patients with refractory gastric cancer.

Presentation Details

Abstract Title: A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma
Abstract Number: TPS515
Presenting Author: Dr. Samuel Cytryn
Session: Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Session Date and Time: 1/23/2025, 11:30 AM-1:00 PM

Complete abstracts will be released at 5:00 PM ET on January 21^st, 2025. Data presented at the conference will be available to view in the publications section of the MiNK website (https://minktherapeutics.com/publications/) following the ASCO GI Meeting.

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.

Forward Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, anticipated benefit, plans and timelines of iNKT cells and encrypted RNA, as well as the collaboration between MiNK and Autonomous Therapeutics. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK and Autonomous undertake no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Investor Contact
917-362-1370
investor@minktherapeutics.com

Media Contact
781-674-4428
communications@minktherapeutics.com

FAQ

What is MiNK Therapeutics (INKT) presenting at ASCO GI 2025?

MiNK Therapeutics is presenting their Phase 2 study of agenT-797 combined with botensilimab/balstilimab for treating refractory gastric cancer.

When and where will INKT's ASCO GI 2025 presentation take place?

The presentation will take place on January 23, 2025, from 11:30 AM-1:00 PM during the Trials in Progress Poster Session in San Francisco, California.

What is the abstract number and title for INKT's ASCO GI presentation?

The abstract number is TPS515, titled 'A phase II study of agenT-797, botensilimab, and balstilimab in patients with advanced, refractory gastroesophageal adenocarcinoma.'

When will INKT's complete ASCO GI abstract be available?

The complete abstract will be released on January 21st, 2025, at 5:00 PM ET.

What type of therapy is INKT's agenT-797?

AgenT-797 is an allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapy developed for treating cancer and other immune-mediated diseases.